Who is sponsoring EMPACT?

EMPACT is sponsored by Seoul St. Mary's Hospital.

What condition does EMPACT study?

EMPACT studies Amyloid Cardiomyopathy.

What drugs are being tested in EMPACT?

Interventions: Enavogliflozin 0.3mg, Placebo.

What is the status of EMPACT?

EMPACT is currently NOT_YET_RECRUITING.

Last reviewed 2025-11-21 · How we verify

Enavogliflozin for the Management of Patients With Amyloid CardiomyopaThy (EMPACT)

NCT07240844 PHASE4 NOT_YET_RECRUITING

This study aims to evaluate the safety and effectiveness of Enavogliflozin 0.3 mg, an SGLT2 inhibitor, in patients with amyloid cardiomyopathy. Participants will take both the study drug and a placebo in two separate periods, with a wash-out period in between. The goal is to determine whether Enavogliflozin is safe and effective for treating amyloid cardiomyopathy.

Details

Lead sponsor	Seoul St. Mary's Hospital
Phase	PHASE4
Status	NOT_YET_RECRUITING
Enrolment	68
Start date	Mon Nov 24 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Mon May 31 2027 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Amyloid Cardiomyopathy

Interventions

Enavogliflozin 0.3mg
Placebo

Countries

South Korea